You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BCMA CAR T-cell therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma, New Diagnosis Tumor Trial in Hangzhou (BCMA CAR-T cells)

Recruiting
  • Multiple Myeloma
  • New Diagnosis Tumor
  • BCMA CAR-T cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Jan 31, 2023

Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T)

Recruiting
  • Multiple Myeloma
  • anti-BCMA CAR-T
  • Tianjin, Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 4, 2023

Relapsed/Refractory Multiple Myeloma Trial in Philadelphia (Cevostamab)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Philadelphia, Pennsylvania
    Hospital of the University of Pennsylvania
Apr 7, 2023

Relapsed/Refractory Multiple Myeloma Trial in New York, Nashville, Salt Lake City (CB-011)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • CB-011
  • New York, New York
  • +3 more
Feb 15, 2023

ITP Trial in Suzhou (autologous anti-BCMA chimeric antigen receptor T cells)

Recruiting
  • ITP
  • autologous anti-BCMA chimeric antigen receptor T cells
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Mar 31, 2022

Multiple Myeloma Trial in United States (Talquetamab)

Recruiting
  • Multiple Myeloma
  • Basking Ridge, New Jersey
  • +6 more
Sep 27, 2023

Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T, VRD-based regimen)

Recruiting
  • Plasma Cell Leukemia
  • anti-BCMA CAR-T
  • VRD-based regimen
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
Aug 4, 2023

Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

Not yet recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • GC012F
  • (no location specified)
Apr 28, 2023

Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T, VRD)

Recruiting
  • Multiple Myeloma
  • anti-BCMA CAR-T
  • VRD
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 5, 2023

Relapse Multiple Myeloma, Refractory Multiple Myeloma Trial in Hangzhou (BCMA Targeted CAR T-cells)

Recruiting
  • Relapse Multiple Myeloma
  • Refractory Multiple Myeloma
  • BCMA Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Medical College, Zhejiang Univers
Jun 18, 2022

CAR-T Cell Therapy Trial in Shanghai (GC012F injection)

Recruiting
  • CAR-T Cell Therapy
  • GC012F injection
  • Shanghai, Shanghai, China
    Department of Rheumatology, Ren Ji Hospital South Campus, School
May 5, 2023

Multiple Myeloma Trial in Shanghai, Wenzhou (Human BCMA Targeted T Cells Injection)

Recruiting
  • Multiple Myeloma
  • Human BCMA Targeted T Cells Injection
  • Shanghai, Shanghai, China
  • +1 more
Dec 7, 2022

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Multiple Myeloma Trial in Xuzhou (anti-BCMA/GPRC5D CAR-T CELL)

Recruiting
  • Multiple Myeloma
  • anti-BCMA/GPRC5D CAR-T CELL
  • Xuzhou, Jiangsu, China
    Kailin Xu
Aug 19, 2022

Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma Trial in Taiyuan (CAR-T Autologous T cell injection)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • CAR-T Autologous T cell injection
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Dec 2, 2022

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in Hangzhou (APRIL CAR-T cells)

Recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • APRIL CAR-T cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
May 3, 2022

Multiple Myeloma, Relapse Multiple Myeloma Trial in Ramat Gan (CAR-BCMA)

Recruiting
  • Multiple Myeloma
  • Relapse Multiple Myeloma
  • CAR-BCMA
  • Ramat Gan, Israel
    Chaim Sheba Medical Center, Tel Hashomer
Feb 7, 2022

Multiple Myeloma Trial in Chicago, Boston, Milwaukee (PHE885)

Recruiting
  • Multiple Myeloma
  • PHE885
  • Chicago, Illinois
  • +4 more
Jul 28, 2022

Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine

Not yet recruiting
  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • Ciltacabtagene Autoleucel
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 2, 2023

Multiple Myeloma Trial in Suzhou (clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells)

Recruiting
  • Multiple Myeloma
  • clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Oct 22, 2021

Relapsed/Refractory Multiple Myeloma Trial in United States (KITE-585, Cyclophosphamide, Fludarabine)

Terminated
Has Results
  • Relapsed/Refractory Multiple Myeloma
  • KITE-585
  • +2 more
  • Los Angeles, California
  • +8 more
Oct 4, 2022

CS1+ or BCMA+ Multiple Myeloma Trial in Wuhan (Conditioning chemo followed by CAR T cell infusion)

Recruiting
  • CS1+ or BCMA+ Multiple Myeloma
  • Conditioning chemotherapy followed by CAR T cell infusion
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Feb 11, 2022

Multiple Myeloma Trial in Worldwide (PHE885)

Recruiting
  • Multiple Myeloma
  • PHE885
  • VIC, Melbourne, Australia
  • +4 more
Jul 20, 2022

Multiple Myeloma Trial in ChongQing (anti-BCMA CAR-T)

Recruiting
  • Multiple Myeloma
  • anti-BCMA CAR-T
  • ChongQing, Chongqing, China
    Department of Hematology, Xinqiao Hospital
Nov 14, 2020

Multiple Myeloma Trial (BMCA and GPRC5D dual target CAR-T cells(OriC321))

Not yet recruiting
  • Multiple Myeloma
  • BMCA and GPRC5D dual target CAR-T cells(OriC321)
  • (no location specified)
Apr 5, 2022